# EDGAR Filing Document

**Accession Number:** 0000879407
**File Stem:** 0000879407-26-000037
**Filing Date:** 2026-3
**Character Count:** 6994
**Document Hash:** fe799e19d0f30108a1bdcc674a4ca4f7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000879407-26-000037.hdr.sgml**: 20260320

**ACCESSION NUMBER**: 0000879407-26-000037

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260319

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260320

**DATE AS OF CHANGE**: 20260320

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ARROWHEAD PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0000879407
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 460408024
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38042
- **FILM NUMBER:** 26778235

**BUSINESS ADDRESS:**
- **STREET 1:** 177 E COLORADO BLVD
- **STREET 2:** SUITE 700
- **CITY:** PASADENA
- **STATE:** CA
- **ZIP:** 91105
- **BUSINESS PHONE:** 626-696-4702

**MAIL ADDRESS:**
- **STREET 1:** 177 E COLORADO BLVD
- **STREET 2:** SUITE 700
- **CITY:** PASADENA
- **STATE:** CA
- **ZIP:** 91105

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ARROWHEAD RESEARCH CORP
- **DATE OF NAME CHANGE:** 20040112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INTERACTIVE GROUP INC
- **DATE OF NAME CHANGE:** 20020509

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INTERACTIVE INC
- **DATE OF NAME CHANGE:** 19940224

?xml version='1.0' encoding='ASCII'? arwr-20260319

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM 8-K**

**CURRENT REPORT** 

**PURSUANT TO SECTION 13 OR 15(D) OF**

**THE SECURITIES EXCHANGE ACT OF 1934** 

March 19, 2026

**Date of Report** 

**(Date of earliest event reported)**

**Arrowhead Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

Delaware 001-38042 46-0408024 <br> (State or other jurisdictionof incorporation) (CommissionFile Number) (IRS EmployerIdentification No.)

177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105

**(Address of principal executive offices, including Zip Code)**

(626) 304-3400

**(Registrant's telephone number, including area code)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| **Securities registered pursuant to Section 12(b) of the Act:** | **Securities registered pursuant to Section 12(b) of the Act:** | **Securities registered pursuant to Section 12(b) of the Act:** |
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.001 per share** | **ARWR** | **The Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders**

The following proposals were submitted to the stockholders of Arrowhead Pharmaceuticals, Inc. (the "Company") at the 2026 Annual Meeting of Stockholders held on March 19, 2026:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ To elect seven directors to serve as members of the Company's Board of Directors until the next Annual Meeting or until their successors are elected;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ To approve, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers (the "Say-on-Pay Proposal");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ To approve the Arrowhead Pharmaceuticals, Inc. Amended and Restated 2021 Incentive Plan; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ To ratify the appointment of KPMG LLP as independent auditors of the Company for the fiscal year ending September 30, 2026.

As of January 22, 2026, the record date for the Annual Meeting, the Company had 140,010,690 shares of its common stock outstanding and entitled to vote. At the Annual Meeting 119,801,542 shares were present in person or represented by proxy and entitled to vote. Based on the votes cast in person and by proxy, each proposal passed, including the election of each director, other than the Say-on-Pay Proposal. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:

***Election of Directors***

---

| | | | | |
|:---|:---|:---|:---|:---|
| <u>NAME</u> | <u>FOR</u> | <u>AGAINST</u> | <u>ABSTAIN</u> | <u>NON-VOTES</u> |
| Christopher Anzalon | 100146366 | 1622011 | 77607 | 17955558 |
| Mauro Ferrar | 99784848 | 1986678 | 74458 | 17955558 |
| Hongbo L | 92692428 | 8971012 | 182544 | 17955558 |
| Adeoye Olukoto | 100808855 | 852631 | 184498 | 17955558 |
| Michael Perr | 70427879 | 31342814 | 75291 | 17955558 |
| Victoria Vakiene | 99264191 | 2506051 | 75742 | 17955558 |
| William Waddill | 91907466 | 9861644 | 256341 | 17955558 |

---

***Advisory Vote to Approve Executive Compensation***

41,625,740 FOR; 59,963,903 AGAINST; 256,341 ABSTAIN; 17,955,558 NON-VOTES

***Vote to Approve the Arrowhead Pharmaceuticals, Inc. Amended and Restated 2021 Incentive Plan***

99,158,276 FOR; 2,401,793 AGAINST; 285,915 ABSTAIN; 17,955,558 NON-VOTES

***Ratification of the appointment of KPMG LLP as independent auditors of the Company***

119,053,168 FOR; 371,668 AGAINST; 376,706 ABSTAIN; 0 NON-VOTES

**Item 9.01. Financial Statements and Exhibits.** 

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 20, 2026

---

| | |
|:---|:---|
| ARROWHEAD PHARMACEUTICALS, INC. | ARROWHEAD PHARMACEUTICALS, INC. |
| By: | /s/ Daniel Apel |
|  | Daniel Apel |
|  | Chief Financial Officer |

---